Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes

In updated biomarker and clinical subgroup analyses from the phase III MONALEESA trials, ribociclib demonstrated consistent improvements in overall survival when added to endocrine therapy in patients with HR-positive/HER2-negative advanced breast cancer.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963148/
https://www.ncbi.nlm.nih.gov/pubmed/35348783
http://dx.doi.org/10.1093/oncolo/oyac010
_version_ 1784677929964273664
author Jacobson, Anne
author_facet Jacobson, Anne
author_sort Jacobson, Anne
collection PubMed
description In updated biomarker and clinical subgroup analyses from the phase III MONALEESA trials, ribociclib demonstrated consistent improvements in overall survival when added to endocrine therapy in patients with HR-positive/HER2-negative advanced breast cancer.
format Online
Article
Text
id pubmed-8963148
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89631482022-03-29 Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes Jacobson, Anne Oncologist Conference Perspectives: Highlights from SABCS In updated biomarker and clinical subgroup analyses from the phase III MONALEESA trials, ribociclib demonstrated consistent improvements in overall survival when added to endocrine therapy in patients with HR-positive/HER2-negative advanced breast cancer. Oxford University Press 2022-03-28 /pmc/articles/PMC8963148/ /pubmed/35348783 http://dx.doi.org/10.1093/oncolo/oyac010 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Perspectives: Highlights from SABCS
Jacobson, Anne
Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title_full Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title_fullStr Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title_full_unstemmed Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title_short Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
title_sort ribociclib improves overall survival in hr+/her2– metastatic breast cancer across common genomic and clinical subtypes
topic Conference Perspectives: Highlights from SABCS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963148/
https://www.ncbi.nlm.nih.gov/pubmed/35348783
http://dx.doi.org/10.1093/oncolo/oyac010
work_keys_str_mv AT jacobsonanne ribociclibimprovesoverallsurvivalinhrher2metastaticbreastcanceracrosscommongenomicandclinicalsubtypes

Ejemplares similares